Business Wire

  1. Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities With $45 Million Equity Investment From NewVale Capital And Telegraph Hill Partners 3/5/2024

    Investment strengthens Argonaut’s leadership position in sterile fill / finish and expands the Company’s aseptic drug product manufacturing capabilities in pre-filled syringes and cartridges.

  2. Paratek Pharmaceuticals Strengthens Senior Leadership Team 6/4/2015

    Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced the addition of two experienced pharmaceutical executives to the company's senior leadership team to meet the company's growing needs as it advances the development program for its lead investigational antibiotic, omadacycline, and as it expands the company's pre-commercialization capabilities.

  3. DCAT Announces Sharp Sourcing 2015 6/2/2015

    The Drug, Chemical & Associated Technologies Association (DCAT) announces DCAT Sharp Sourcing 2015, a conference and networking event for pharmaceutical, biopharmaceutical companies and suppliers in the pharmaceutical manufacturing value chain. 

  4. Bioserv Corporation And Advantar Laboratories Announce Collaboration To Create A Comprehensive Value Chain 3/18/2013

    Bioserv Corporation, a leading provider of pharmaceutical cGMP contract manufacturing, clinical packaging and cold chain and distribution services, is pleased to announce that it has entered into a non-exclusive Collaboration Agreement with Advantar Laboratories Inc., a provider of high-quality, customer service driven analytical testing, biophysical characterization, drug product formulation and litigation support services to pharmaceutical and biotechnology companies.

  5. BioInvent Recruits New Chief Executive Officer 1/9/2013

    BioInvent International AB recently announced that Svein Mathisen has resigned from his positions as chief executive officer of the Company and as member of the Board of Directors.

  6. LipoScience Receives FDA Clearance for Vantera Clinical Analyzer 9/5/2012

    LipoScience, Inc., an in vitro diagnostic company, announced that it has received 510(k) clearance from the FDA to market the Vantera® Clinical Analyzer, which is the first NMR analyzer designed specifically for the clinical laboratory.  

  7. Baxter Initiates Phase I Clinical Trial With Anti-MIF Antibody In Patients With Solid Tumors 9/5/2012

    Baxter International Inc. has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company’s efforts to extend its oncology portfolio with advanced biological research and development.

  8. Edimer Receives FDA Fast Track Designation For Lead Compound EDI200 6/14/2012

    Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), recently announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company’s novel, proprietary, recombinant protein.

  9. Bristol-Myers Squibb And Gilead Sciences Announce Licensing Agreement for Development And Commercialization Of New Fixed-Dose Combination Pill For People Living With HIV 10/27/2011
    Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ®(atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
  10. Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer's Disease Diagnosis 10/27/2011
    Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.